Eva Hadaschik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eva Hadaschik has a total of 252 co-authors. Here are the top co-authors by number of shared publications:
- Dirk Schadendorf
Department of Dermatology, University Hospital Essen, University Duisburg-Essen, Essen, Germany
68 shared publications - Klaus Georg Griewank
Department of Dermatology, Venereology and Allergology, University Hospital Essen , Essen
68 shared publications - Antje Sucker
University Hospital Essen 1 Essen
65 shared publications - Anne Zaremba
University Hospital Essen 1 Essen
61 shared publications - Annette Paschen
Department of Dermatology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
59 shared publications - Alexander Roesch
Department of Dermatology, University Hospital Essen, 45147 Essen, Germany
56 shared publications
Latest Publications
- Open Access
- 22 March 2026
- Published by Elsevier in EJC Skin Cancer
- Vol. 4
PD-L1 assessment in Merkel cell carcinoma: Predictive implications for anti-PD-1 and anti-PD-L1 therapy
- 22 March 2026
- Published by Elsevier in EJC Skin Cancer
- Vol. 4
Open AccessPD-L1 assessment in Merkel cell carcinoma: Predictive implications for anti-PD-1 and anti-PD-L1 therapy
- Open Access
- 11 December 2025
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 23 (12) , 1555-1565
Klinisches und immunpathologisches Spektrum des Immunglobulin‐M‐Pemphigoids: eine multizentrische Fallserie
Zusammenfassung: Hintergrund und Zielsetzung: Die Pemphigoid‐Erkrankungen werden primär durch IgG‐ oder IgA‐Autoantikörper gegen die kutane Basalmembranzone (BMZ) vermittelt. Obwohl rezente Arbeiten auf die Existenz einer ausschließlich IgM‐vermittelten Pemphigoid‐Erkrankung hindeuten, fehlt bislang eine umfassendere Untersuchung. Patienten und Methodik: In dieser prospektiven multizentrischen Studie wurden zehn Patienten mit ausschließlich IgM‐Ablagerungen entlang der BMZ in der direkten Immunfluoreszenz (IF) eingeschlossen. Zirkulierende IgM‐Autoantikörper wurden mittels indirekter IF und Immunoblot mit rekombinantem BP180 nachgewiesen. Ergebnisse: Die Kohorte umfasste vier Frauen und sechs Männer mit einem medianen Alter von 77 Jahren, die überwiegend Prurigo‐artige Hautveränderungen ohne Blasenbildung und Schleimhautbeteiligung aufwiesen. In der indirekten IF auf NaCl‐separierter humaner Spalthaut zeigten die Seren von neun Patienten lineare IgM‐Ablagerungen am Dach der artifiziellen Blase. Bei vier Patienten konnte eine IgM‐Reaktivität gegen BP180 nachgewiesen werden, bei keinem jedoch gegen BP230. Bei keinem der Kontrollpatienten (n = 100) wurden IgM‐Ablagerungen an der BMZ in der direkten IF beobachtet. Eine IgM‐Reaktivität gegen die BMZ im Serum wurde bei 1 von 30 Kontrollpatienten mit chronischem Pruritus beziehungsweise bei 3 von 60 Kontrollpatienten ohne chronischen Pruritus nachgewiesen. Schlussfolgerungen: Das IgM‐Pemphigoid ist durch gewebsgebundene, exklusive IgM‐Autoantikörper gegen die BMZ, serologische IgM‐Reaktivität mit BP180 als primärem Zielantigen, überwiegend nichtbullösen klinischen Phänotyp, fehlende Schleimhautbeteiligung und eher milden Krankheitsverlauf gekennzeichnet. Unsere Ergebnisse deuten darauf hin, dass das IgM‐Pemphigoid eine eigenständige Entität darstellen könnte.
- 11 December 2025
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 23 (12) , 1555-1565
Open AccessKlinisches und immunpathologisches Spektrum des Immunglobulin‐M‐Pemphigoids: eine multizentrische Fallserie
Zusammenfassung: Hintergrund und Zielsetzung: Die Pemphigoid‐Erkrankungen werden primär durch IgG‐ oder IgA‐Autoantikörper gegen die kutane Basalmembranzone (BMZ) vermittelt. Obwohl rezente Arbeiten auf die Existenz einer ausschließlich IgM‐vermittelten Pemphigoid‐Erkrankung hindeuten, fehlt bislang eine umfassendere Untersuchung. Patienten und Methodik: In dieser prospektiven multizentrischen Studie wurden zehn Patienten mit ausschließlich IgM‐Ablagerungen entlang der BMZ in der direkten Immunfluoreszenz (IF) eingeschlossen. Zirkulierende IgM‐Autoantikörper wurden mittels indirekter IF und Immunoblot mit rekombinantem BP180 nachgewiesen. Ergebnisse: Die Kohorte umfasste vier Frauen und sechs Männer mit einem medianen Alter von 77 Jahren, die überwiegend Prurigo‐artige Hautveränderungen ohne Blasenbildung und Schleimhautbeteiligung aufwiesen. In der indirekten IF auf NaCl‐separierter humaner Spalthaut zeigten die Seren von neun Patienten lineare IgM‐Ablagerungen am Dach der artifiziellen Blase. Bei vier Patienten konnte eine IgM‐Reaktivität gegen BP180 nachgewiesen werden, bei keinem jedoch gegen BP230. Bei keinem der Kontrollpatienten (n = 100) wurden IgM‐Ablagerungen an der BMZ in der direkten IF beobachtet. Eine IgM‐Reaktivität gegen die BMZ im Serum wurde bei 1 von 30 Kontrollpatienten mit chronischem Pruritus beziehungsweise bei 3 von 60 Kontrollpatienten ohne chronischen Pruritus nachgewiesen. Schlussfolgerungen: Das IgM‐Pemphigoid ist durch gewebsgebundene, exklusive IgM‐Autoantikörper gegen die BMZ, serologische IgM‐Reaktivität mit BP180 als primärem Zielantigen, überwiegend nichtbullösen klinischen Phänotyp, fehlende Schleimhautbeteiligung und eher milden Krankheitsverlauf gekennzeichnet. Unsere Ergebnisse deuten darauf hin, dass das IgM‐Pemphigoid eine eigenständige Entität darstellen könnte.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance
No chromosomal alterations in the MHC region of HLA-II-loss JAK1/2 mutant melanoma cells
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance
No chromosomal alterations in the MHC region of HLA-II-loss JAK1/2 mutant melanoma cells
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance
HLA-II expression in longitudinal melanoma samples
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance
HLA-II expression in longitudinal melanoma samples
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance
Homogeneous HLA-I and PD-L1 expression in consecutive melanoma samples from patient Ma-Mel-61
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance
Homogeneous HLA-I and PD-L1 expression in consecutive melanoma samples from patient Ma-Mel-61
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance
CD4 T-cell sensitivity of constHLA-II melanoma cells
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance
CD4 T-cell sensitivity of constHLA-II melanoma cells
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance
JAK inhibition downregulates HLA-II but not HLA-I or PD-L1 expression in melanoma cells
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance
JAK inhibition downregulates HLA-II but not HLA-I or PD-L1 expression in melanoma cells
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance
ConstHLA-II melanoma cells lack endogenous interferon expression
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance
ConstHLA-II melanoma cells lack endogenous interferon expression
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance
HLA-II APM transcript levels in melanoma biopsies from ICB-treated patients
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance
HLA-II APM transcript levels in melanoma biopsies from ICB-treated patients
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Data from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance
Purpose:Recent studies have demonstrated HLA class II (HLA-II)–dependent killing of melanoma cells by cytotoxic CD4 T cells. We investigated evolution of HLA-II–loss tumors that escape cytotoxic CD4 T-cell activity and contribute to immunotherapy resistance.Experimental Design:Melanoma cells from longitudinal metastases were studied for constitutive and IFN-inducible HLA-II expression, sensitivity towards autologous CD4 T cells, and immune evasion by HLA-II loss. Clinical significance of HLA-II–low tumors was determined by analysis of transcriptomic data sets from patients with immune checkpoint blockade (ICB).Results:Analysis of longitudinal samples revealed strong intermetastatic heterogeneity in melanoma cell–intrinsic HLA-II expression and subclonal HLA-II loss. Tumor cells from early lesions either constitutively expressed HLA-II, sensitizing to cytotoxic CD4 T cells, or induced HLA-II and gained CD4 T-cell sensitivity in the presence of IFNγ. In contrast, late outgrowing subclones displayed a stable CD4 T-cell–resistant HLA-II–loss phenotype. These cells lacked not only constitutive but also IFNγ-inducible HLA-II due to JAK1/2-STAT1 pathway inactivation. Coevolution of JAK1/2 deficiency and HLA-II loss established melanoma cross-resistance to IFNγ and CD4 T cells, as detected in distinct stage IV metastases. In line with their immune-evasive phenotype, HLA-II–low melanomas showed reduced CD4 T-cell infiltrates and correlated with disease progression under ICB.Conclusions:Our study links melanoma resistance to CD4 T cells, IFNγ, and ICB at the level of HLA-II, highlighting the significance of tumor cell–intrinsic HLA-II antigen presentation in disease control and calling for strategies to overcome its downregulation for improvement of patient outcome.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance
Purpose:Recent studies have demonstrated HLA class II (HLA-II)–dependent killing of melanoma cells by cytotoxic CD4 T cells. We investigated evolution of HLA-II–loss tumors that escape cytotoxic CD4 T-cell activity and contribute to immunotherapy resistance.Experimental Design:Melanoma cells from longitudinal metastases were studied for constitutive and IFN-inducible HLA-II expression, sensitivity towards autologous CD4 T cells, and immune evasion by HLA-II loss. Clinical significance of HLA-II–low tumors was determined by analysis of transcriptomic data sets from patients with immune checkpoint blockade (ICB).Results:Analysis of longitudinal samples revealed strong intermetastatic heterogeneity in melanoma cell–intrinsic HLA-II expression and subclonal HLA-II loss. Tumor cells from early lesions either constitutively expressed HLA-II, sensitizing to cytotoxic CD4 T cells, or induced HLA-II and gained CD4 T-cell sensitivity in the presence of IFNγ. In contrast, late outgrowing subclones displayed a stable CD4 T-cell–resistant HLA-II–loss phenotype. These cells lacked not only constitutive but also IFNγ-inducible HLA-II due to JAK1/2-STAT1 pathway inactivation. Coevolution of JAK1/2 deficiency and HLA-II loss established melanoma cross-resistance to IFNγ and CD4 T cells, as detected in distinct stage IV metastases. In line with their immune-evasive phenotype, HLA-II–low melanomas showed reduced CD4 T-cell infiltrates and correlated with disease progression under ICB.Conclusions:Our study links melanoma resistance to CD4 T cells, IFNγ, and ICB at the level of HLA-II, highlighting the significance of tumor cell–intrinsic HLA-II antigen presentation in disease control and calling for strategies to overcome its downregulation for improvement of patient outcome.